Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S Announces Final US Court Judgment in Favor of Arzerra and GlaxoSmithKline Plc in Patent Infringement Lawsuit


Tuesday, 16 Apr 2013 02:10pm EDT 

Genmab A/S announced that the United States (US) Court of Appeals for the Federal Circuit has upheld the US District Court’s judgment in favor of GlaxoSmithKline Plc (GSK) in a patent infringement case involving Genmab's Arzerra brought against GSK by Genentech and Biogen Idec. The two companies appealed the court order on the patent claim construction which led to the judgment in favor of GSK in December 2011. The US Court of Appeals for the Federal Circuit has upheld the District Court’s original decision and the lawsuit is now over unless Genentech and Biogen Idec are granted further review by the Federal Circuit or the Supreme Court. Genentech and Biogen Idec originally filed the lawsuit in 2010 with the US District Court for the Southern District of California claiming Arzerra infringed US Patent No. 7,682,612 covering methods of treating Chronic Lymphocytic Leukemia (CLL) with CD20 antibodies. GSK denied infringement and claimed the patent was invalid and unenforceable. Arzerra, Genmab’s CD20 antibody, is partnered with GSK and is marketed in the US and Europe as well as other territories. 

Company Quote

43.35
0.06 +0.14%
19 Dec 2014